Prevalence and Implications of HIV Superinfection

Prema Menezes^*
*Correspondence: Prema Menezes, Department of Medicine, University of North Carolina at Chapel Hill, USA, Email:

Introduction

In 2002, information introduced at the XIV International AIDS Conference raised a frightening new possibility for individuals living with HIV. Bruce Walker M.D., a conspicuous clinician-specialist at Harvard's Massachusetts General Hospital, detailed that a man living with HIV had been superinfected with a subsequent HIV strain. A past report of superinfection in 2000 had ended up being a bogus alert, however the Walker case was affirmed and two other case reports were additionally distributed that very year.Indeed, even subsequent to taking care of the shock of an underlying conclusion, these discoveries caused it to appear to be that HIV-positive individuals were not liberated from worries that they may be superinfected with another HIV strain-and possibly one that was more harmful than their current infection,Andrew Redd, Ph.D.,at NIAID was captivated. "Indeed, HIV superinfection happens, yet [reporting on superinfection] was generally narrative," he says. "I was keen on how regularly super infection happens [1,2].

Description

In one case the patient's second strain of HIV was drug-safe. He likewise encountered a repeat of intense HIV side effects which required hospitalization for suspected meningitis and a huge, however brief reduction in CD4 count. In the other case the patient's unique strain of HIV, which was drug-safe, was supplanted by an obviously more grounded non-safe strain and his viral burden expanded from around 3000 to a large portion of 1,000,000. Anyway he kept a CD4 count north of 1000 and his viral burden had gotten back to 3000 per year after the fact [3].

In this imminent review at the Royal Free and Royal London Hospitals, gay men who were determined to have HIV, didn't begin HIV treatment, kept on having unprotected butt-centric sex after finding, and had a more than triple (0.5 log) expansion in their viral burden during routine subsequent arrangements were approached to have their HIV hereditarily investigated in more detail. The eight men who met these measures and joined the review were analyzed somewhere in the range of 2004 and 2008 and their normal age was 30, more youthful than the normal age for finding in gay men [4,5].

The immunological aspects of HIV-SI are inherently related to HIV vaccinology, and the initial studies that described HIV-SI all highlighted the significance of their finding on this field. These studies, and others that have observed HIV-SI in a variety of populations, provide a sobering fact for HIV vaccine design, i.e. that natural HIV infection and the host’s subsequent immune responses are not fully protective against a new HIV challenge. However, these findings also provide investigators with unique populations and novel research paths to identify which components of the natural HIV immune response may be protective against HIV-SI, which components are not protective, and what happens to the immune response after a second successful HIV viral challenge [6].

Conclusion

Anyway five months after disease he encountered an arrival of similar side effects, requiring hospitalization and a MRI check for suspected meningitis,His viral burden returned to 160,000 and accordingly expanded further to almost 1,000,000. His CD4 count fell briefly from 430 to 240 cells/mm3 however it therefore bounced back to around 390 cells/mm3. He kept on having highhazard sex and over the course of the following a half year likewise obtained first contaminations of syphilis and herpes. His subsequent infection had two opposition changes to nucleoside drugs.

References

1. Chen, Ding-Shinn, George C Kuo, Juei Low Sung and Ming Yang Lai, et al. "Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience." J Infect Dis 4 (1990): 817-822.

Google Scholar, Crossref

2. Huang, YenTsung, Chin Lan Jen, Hwai I Yang and Mei Hsuan Lee et al. "Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C." J Clin Oncol 27 (2011): 3643.

Google Scholar, Crossref

3. Crespo, J Lozano, F De La Cruz, L Rodrigo and  M Rodriguez, et al. "Prevalence and significance of hepatitis C viremia in chronic active hepatitis B." Am J Gastroenterol8 (1994).

Google Scholar, Crossref

4. Liaw, YunFan, Joseph JY Sung, Wan Cheng Chow and Geoffrey Farrell, et al. "Lamivudine for patients with chronic hepatitis B and advanced liver disease." N Engl J Med 15 (2004): 1521-1531.

Google Scholar, Crossref

5. Liu, Chun Jen, Wan Long Chuang, I Shyan Sheen and Horng Yuan Wang,et al. "Efficacy of ledipasvir and sofos buvir treatment of HCV infection in patients coinfected with HBV." Gastroenterology 4 (2018): 989-997.

Google Scholar, Crossref

6. Sung, JueiLow, The Hong Wang and Jui Yun Yu. "Clinical study on primary carcinoma of the liver in Taiwan." The American Journal of Digestive Diseases 12 (1967): 1036-1049.

Google Scholar, Crossref